GlycoVaxyn

About:

GlycoVaxyn develops and manufactures biological conjugation vaccines against bacterial infections utilizing recombinant DNA technology.

Website: http://www.glycovaxyn.com/

Top Investors: Index Ventures, Edmond de Rothschild Private Equity, Sofinnova Partners

Description:

GlycoVaxyn AG, a vaccine biopharmaceutical company, develops and manufactures biological conjugation vaccines against bacterial infections utilizing recombinant DNA technology. It develops and produces immunogenic glycoprotein conjugates vaccines for a range of bacterial diseases, such as pneumococcal and nosocomial infections.

Total Funding Amount:

$34.3M

Headquarters Location:

Schlieren, Zurich, Switzerland

Founded Date:

2004-01-01

Founders:

Number of Employees:

11-50

Last Funding Date:

2010-05-04

IPO Status:

Private

Industries:

© 2025 bioDAO.ai